Harmonised health technology assessment in Europe? There’s a long way to go
Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices and culture
Market Access/ Views & Analysis/ Views and analysis
Leela Barham
drug market access, Health Technology Assessment, HTA, Leela Barham, market access
0 Comment
Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices and culture
Articles/ Pharma Market Access/ UK & Europe/ Views and analysis
Leela Barham
drug market access, Drug pricing, NICE, pharma market access, Pharmaceutical Price Regulation Scheme, PPRS, UK drug market
0 Comment
Should there be a different review of NICE as part of a successor PPRS?
Articles/ Cancer/ Pharma Market Access/ Views and analysis
Linda Banks
cancer, cancer drug, drug market access, drug prices, Oncology
0 Comment
The cost: benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them.
Articles/ Deep Dive/ Pharma Market Access/ Views and analysis
Linda Banks
Deep Dive, drug market access, HTA, market access, patient advocacy groups
0 Comment
Eric Low shares his views on why hurdles remain to new drug access.
Articles/ Deep Dive/ Pharma Market Access/ Views and analysis
Linda Banks
biosimilars, drug market access, Drug regulation, market access, regulatory pathway
0 Comment
Though they can reduce the costs of health care, biosimilars still face challenges to access.
Articles/ Pharma Market Access/ UK & Europe/ Views and analysis
Leela Barham
drug market access, Leela Barham, market access, medicines assessment, NHS, NHSE, Pharmaceutical Price Regulation Scheme, PPRS
0 Comment
Has the PPRS delivered on the aim of reducing bureaucracy and duplication?
Articles/ Deep Dive/ Pharma Market Access/ Views and analysis
Linda Banks
drug market access, Health Technology Assessment, HTA, HTA impact, market access
0 Comment
Examining the true impact of a positive health technology assessment (HTA).
Articles/ Deep Dive/ Pharma Market Access/ Views and analysis
Linda Banks
data management, Deep Dive, drug market access, market access, Partnerships, stakeholder needs
0 Comment
The steps required for successful market access.
Articles/ Deep Dive/ Pharma Market Access/ Views and analysis
Linda Banks
big data, data management, Deep Dive, drug market access, market access, pricing strategy
0 Comment
Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.